Results 251 to 260 of about 11,906,519 (291)
Pleurodesis Is Inhibited by Anti-Vascular Endothelial Growth Factor Antibody
Chest, 2005 The intrapleural injection of transforming growth factor (TGF)-beta2 produces pleurodesis in rabbits associated with large pleural effusions. This study investigated whether anti-vascular endothelial growth factor (VEGF) antibody has any effect on the fluid production or the pleurodesis induced by TGF-beta2.Three groups of seven New Zealand white ...
Ioannis Kalomenidis +2 more
exaly +4 more sources
Ten Years of Anti-Vascular Endothelial Growth Factor Therapy [PDF]
Nature Reviews Drug Discovery, 2016 The targeting of vascular endothelial growth factor A (VEGFA), a crucial regulator of both normal and pathological angiogenesis, has revealed innovative therapeutic approaches in oncology and ophthalmology. The first VEGFA inhibitor, bevacizumab, was approved by the US Food and Drug Administration in 2004 for the first-line treatment of metastatic ...
Napoleone Ferrara, Anthony P Adamis
exaly +5 more sources
Anti-Vascular Endothelial Growth Factor Therapy in Breast Cancer
International Journal of Molecular Sciences, 2014 Neo-angiogenesis is a critical process for tumor growth and invasion and has become a promising target in cancer therapy. This manuscript reviews three currently relevant anti-angiogenic agents targeting the vascular endothelial growth factor system: bevacizumab, ramucirumab and sorafenib. The efficacy of anti-angiogenic drugs in adjuvant therapy or as
Daniela Grimm +2 more
exaly +4 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Anti-Vascular Endothelial Growth Factor Therapy for Radiation Retinopathy
Ophthalmic Surgery, Lasers and Imaging Retina, 2020BACKGROUND AND OBJECTIVE: The purpose of this article is to review the role of anti-vascular endothelial growth factor (VEGF) therapy in treating patients with radiation retinopathy (RR). PATIENTS AND METHODS: RR can be associated with a significant decrease in visual acuity (VA ...
Nadim, Rayess, Prithvi, Mruthyunjaya
openaire +2 more sources
Use of anti‐vascular endothelial growth factor in the management of pterygium
Acta Ophthalmologica, 2016AbstractThe rising success of anti‐vascular endothelial growth factor (VEGF) therapies in ocular disease has stimulated the use of such treatments in the surgical management of pterygium. We reviewed the literature to better understand the safety and efficacy of the adjunctive role of anti‐VEGF treatments for pterygium excision.
Renata Kiri Mak +7 more
openaire +4 more sources
Anti-vascular endothelial growth factor agents for diabetic maculopathy
British Journal of Ophthalmology, 2009The management of diabetic macular oedema is changing. The therapeutic armamentarium for diabetic macular oedema (DMO) includes a new group of drugs that inhibit vascular endothelial growth factor (VEGF). These anti-VEGF agents are already being used widely in DMO in clinical practice despite that several phase III trials on these drugs are still ...
A, Salam, J, DaCosta, S, Sivaprasad
openaire +2 more sources
Anti-vascular endothelial growth factor and retinopathy of prematurity
British Journal of Ophthalmology, 2008Retinopathy of prematurity1 (ROP) has been at the nexus of a progressive understanding of neovascularisation, in large part because of the mouse model of oxygen-induced retinopathy (OIR) developed by Lois Smith.2 This model has been very instructive, because it has crystallised the hypothesis that ROP in general is caused by a two-step or two-phase ...
openaire +2 more sources
Anti‐vascular endothelial growth factor for myopic choroidal neovascularization
Clinical & Experimental Ophthalmology, 2012AbstractMyopic choroidal neovascularization (CNV) is a vision‐threatening complication in the eyes with pathological myopia, which is particularly prevalent among young and middle‐aged Asians globally. To date, the verteporfin in photodynamic therapy study is the only randomized‐controlled study in treatment of subfoveal myopic CNV.
Danny S, Ng +2 more
openaire +2 more sources